This is an edited version of an article by Carolyn Seymour published in OncLive Mar 28, 2023
Neoadjuvant treatment with olaparib (Lynparza) prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer, according to findings from the phase 1 NOW trial (NCT03943173) presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
With a follow-up of 11.7 months (range, 2.0-32.2), the estimated 12-month progression-free survival rate was 81% (42%-95%).
“Surgical outcomes [were] outstanding with only 2 cycles, even in stage IV disease. [Additionally, we saw an] expected safety profile during olaparib window treatment,” presenting study author Shannon N. Westin, MD, MPH, professor in the Department of Reproductive Medicine at The University of Texas MD Anderson Cancer Center in Houston, said in a presentation.
NOW is a single-arm, open-label pilot study.2 The primary objective was to determine the feasibility of administering olaparib in the neoadjuvant setting for patients with advanced, high-grade, BRCA-mutant ovarian cancer.1 Secondary objectives included efficacy and the proportion of patients able to undergo interval tumor reductive surgery; complete pathologic response; and toxicity. …